TDMS Study 05101-01 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
METHYL BROMIDE
NTP Experiment-Test: 05101-01 Report: PEIRPT05
Study Type: CHRONIC Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
Facility: Brookhaven National Laboratory
Chemical CAS #: 74-83-9
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL CONTROL CONTROL 10 PPM 10 PPM 10 PPM
INTERIM TERMINAL NEURO INTERIM TERMINAL NEURO
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 21 50 15 20 50 16
Scheduled Sacrifice 19 9 20 7
Early Deaths
Moribund Sacrifice 1 4 5 1
Dead 1 6 3 1
Moribund 3 1
Survivors
Moribund Sacrifice 1
Terminal Sacrifice 36 6 41 7
Animals Examined Microscopically 20 50 20 50 2
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (20) (50) (20) (50) (2)
Intestine Small, Ileum (20) (49) (20) (50) (2)
Liver (20) (50) (20) (50) (2)
Hepatocellular Carcinoma 4 (8%) 3 (6%)
Hepatocellular Carcinoma, Multiple 1 (2%)
Hepatocellular Adenoma 5 (10%) 7 (14%) 1 (50%)
Hepatocellular Adenoma, Multiple 1 (2%)
Histiocytic Sarcoma, Metastatic, Spleen 2 (4%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%) 1 (2%)
Pancreas (20) (50) (20) (50) (2)
Histiocytic Sarcoma, Metastatic, Spleen 2 (4%)
Acinus, Carcinoma 1 (2%)
Salivary Glands (20) (49) (20) (49) (2)
Histiocytic Sarcoma, Metastatic, Spleen 1 (2%)
Stomach (20) (50) (20) (50) (2)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (20) (50) (20) (50) (2)
Carcinoma, Metastatic, Kidney 1 (2%)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL CONTROL CONTROL 10 PPM 10 PPM 10 PPM
INTERIM TERMINAL NEURO INTERIM TERMINAL NEURO
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (19) (50) (20) (50) (2)
Carcinoma, Metastatic, Kidney 1 (2%)
Adrenal Gland, Medulla (19) (50) (20) (50) (2)
Pheochromocytoma Benign 1 (2%)
Pituitary Gland (18) (49) (18) (48) (2)
Pars Distalis, Adenoma 5 (10%) 4 (8%)
Pars Distalis, Carcinoma 1 (2%)
Thyroid Gland (19) (49) (20) (49) (2)
Histiocytic Sarcoma, Metastatic, Spleen 1 (2%)
Follicular Cell, Adenoma 1 (2%) 3 (6%)
Follicular Cell, Adenoma, Multiple 1 (2%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (20) (50) (20) (49) (2)
Cystadenoma 2 (4%)
Histiocytic Sarcoma, Metastatic, Spleen 1 (2%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Uterus (20) (50) (20) (50) (2)
Histiocytic Sarcoma 2 (4%) 2 (4%)
Leiomyoma 1 (2%)
Polyp Stromal 1 (2%) 1 (2%) 1 (50%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (20) (50) (20) (50) (2)
Hemangiosarcoma 1 (5%)
Lymph Node (13) (49) (10) (50) (2)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Lymph Node, Bronchial (7) (25) (7) (32)
Carcinoma, Metastatic, Kidney 1 (3%)
Histiocytic Sarcoma, Metastatic, Spleen 1 (4%)
Lymph Node, Mandibular (1) (42) (40) (1)
Histiocytic Sarcoma, Metastatic, Spleen 2 (5%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Lymph Node, Mediastinal (7) (18) (7) (17)
Carcinoma, Metastatic, Kidney 1 (6%)
Page 3
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL CONTROL CONTROL 10 PPM 10 PPM 10 PPM
INTERIM TERMINAL NEURO INTERIM TERMINAL NEURO
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Histiocytic Sarcoma, Metastatic, Spleen 1 (6%)
Lymph Node, Mesenteric (44) (47) (1)
Histiocytic Sarcoma, Metastatic, Spleen 3 (7%)
Spleen (20) (50) (20) (50) (2)
Hemangiosarcoma 1 (5%) 1 (2%)
Histiocytic Sarcoma 3 (6%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Thymus (20) (45) (19) (40) (1)
Carcinoma, Metastatic, Pancreas 1 (2%)
Hemangiosarcoma, Metastatic, Heart 1 (3%)
Histiocytic Sarcoma, Metastatic, Spleen 1 (2%)
Thymoma NOS 2 (5%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (17) (38) (17) (35) (2)
Adenocarcinoma 1 (3%)
Skin (20) (50) (20) (50) (2)
Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Tail, Keratoacanthoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (20) (50) (20) (50) (2)
Osteosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (20) (50) (20) (50) (2)
Peripheral Nerve (20) (49) (20) (50) (2)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (20) (50) (20) (50) (2)
Alveolar/Bronchiolar Adenoma 3 (6%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 2 (4%)
Carcinoma, Metastatic, Liver 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma, Metastatic, Spleen 2 (4%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Page 4
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL CONTROL CONTROL 10 PPM 10 PPM 10 PPM
INTERIM TERMINAL NEURO INTERIM TERMINAL NEURO
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1) (1)
Adenoma 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (20) (50) (20) (50) (2)
Carcinoma, Metastatic 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Histiocytic Sarcoma, Metastatic, Spleen 1 (2%)
Urinary Bladder (20) (50) (19) (50) (2)
Histiocytic Sarcoma, Metastatic, Spleen 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(20) *(50) *(20) *(50) *(2)
Histiocytic Sarcoma 5 (10%) 2 (4%)
Lymphoma Malignant Mixed 4 (8%) 4 (8%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL CONTROL CONTROL 10 PPM 10 PPM 10 PPM
INTERIM TERMINAL NEURO INTERIM TERMINAL NEURO
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 1 27 29 2
Total Primary Neoplasms 2 42 37 2
Total Animals with Benign Neoplasms 16 16 2
Total Benign Neoplasms 23 19 2
Total Animals with Malignant Neoplasms 1 16 15
Total Malignant Neoplasms 2 19 16
Total Animals with Metastatic Neoplasms 6 6
Total Metastatic Neoplasm 29 10
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 2
Total Uncertain Neoplasms 2
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 33 PPM 33 PPM 33 PPM 100 PPM 100 PPM 100 PPM
INTERIM TERMINAL NEURO INTERIM TERMINAL NEURO
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 20 50 16 10 60 16
Scheduled Sacrifice 20 8 8 8
Early Deaths
Moribund Sacrifice 3 4
Dead 1 1 4
Moribund 1 1 2 12 2
Survivors
Terminal Sacrifice 45 6 40 6
Animals Examined Microscopically 20 50 2 10 60 2
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (17) (49) (1) (10) (58) (2)
Intestine Large, Cecum (20) (50) (2) (10) (58) (2)
Intestine Large, Colon (20) (50) (2) (10) (60) (2)
Intestine Small, Duodenum (20) (50) (2) (10) (58) (2)
Adenoma 1 (2%)
Intestine Small, Ileum (20) (49) (2) (10) (58) (2)
Liver (20) (50) (2) (10) (60) (2)
Hepatocellular Carcinoma 2 (4%) 1 (2%)
Hepatocellular Adenoma 6 (12%) 4 (7%)
Hepatocellular Adenoma, Multiple 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Pancreas (20) (50) (2) (10) (60) (2)
Hemangioma 1 (2%)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Salivary Glands (20) (50) (2) (10) (60) (2)
Stomach (20) (50) (2) (10) (60) (2)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (20) (50) (2) (10) (59) (2)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (20) (50) (2) (10) (59) (2)
Adrenal Gland, Medulla (20) (50) (2) (10) (59) (2)
Pheochromocytoma Benign 1 (5%)
Islets, Pancreatic (20) (50) (2) (10) (60) (2)
Adenoma 1 (2%)
Page 7
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 33 PPM 33 PPM 33 PPM 100 PPM 100 PPM 100 PPM
INTERIM TERMINAL NEURO INTERIM TERMINAL NEURO
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Pituitary Gland (19) (48) (1) (10) (55) (2)
Pars Distalis, Adenoma 2 (4%) 1 (2%)
Thyroid Gland (20) (50) (1) (9) (60) (2)
Follicular Cell, Adenoma 2 (4%) 2 (3%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (20) (50) (2) (10) (58) (2)
Cystadenoma 1 (2%) 3 (5%)
Uterus (20) (50) (2) (10) (60) (2)
Polyp Stromal 3 (6%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (20) (50) (2) (10) (60) (2)
Lymph Node (11) (50) (2) (7) (57) (2)
Pancreatic, Histiocytic Sarcoma, Metastatic,
Liver 1 (2%)
Lymph Node, Bronchial (7) (31) (1) (4) (30) (1)
Lymph Node, Mandibular (43) (46) (1)
Lymph Node, Mediastinal (5) (14) (5) (13)
Lymph Node, Mesenteric (48) (2) (1) (55) (1)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Spleen (20) (50) (2) (10) (60) (2)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Marked 1 (2%)
Hemangiosarcoma, Moderate 1 (2%)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%) 1 (2%)
Thymus (20) (43) (1) (9) (51) (1)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (18) (38) (1) (10) (51) (2)
Carcinoma 1 (2%)
Skin (20) (50) (2) (10) (60) (2)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 33 PPM 33 PPM 33 PPM 100 PPM 100 PPM 100 PPM
INTERIM TERMINAL NEURO INTERIM TERMINAL NEURO
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1)
Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (20) (50) (2) (10) (60) (2)
Spinal Cord (20) (50) (2) (10) (59) (2)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (20) (50) (2) (10) (60) (2)
Alveolar/Bronchiolar Adenoma 1 (50%) 6 (10%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Osteosarcoma, Metastatic 1 (2%)
Nose (20) (50) (2) (10) (60) (2)
Osteosarcoma, Metastatic 1 (2%)
Trachea (19) (50) (2) (9) (60) (2)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1)
Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (20) (50) (2) (10) (60) (2)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%) 1 (2%)
Urinary Bladder (20) (50) (1) (10) (59) (2)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(20) *(50) *(2) *(10) *(60) *(2)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymphoma Malignant Lymphocytic 3 (6%) 1 (2%)
Lymphoma Malignant Mixed 5 (10%) 6 (10%)
Lymphoma Malignant Undifferentiated Cell 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 9
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 33 PPM 33 PPM 33 PPM 100 PPM 100 PPM 100 PPM
INTERIM TERMINAL NEURO INTERIM TERMINAL NEURO
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 1 27 1 27
Total Primary Neoplasms 1 31 1 34
Total Animals with Benign Neoplasms 1 15 1 18
Total Benign Neoplasms 1 16 1 20
Total Animals with Malignant Neoplasms 15 14
Total Malignant Neoplasms 15 14
Total Animals with Metastatic Neoplasms 1 4
Total Metastatic Neoplasm 3 9
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 10
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL CONTROL CONTROL 10 PPM 10 PPM 10 PPM
INTERIM TERMINAL NEURO INTERIM TERMINAL NEURO
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 20 50 16 20 49 16
Scheduled Sacrifice 20 10 19 8
Early Deaths
Dead 5 1 8
Moribund Sacrifice 2 4
Accident 1
Survivors
Terminal Sacrifice 40 6 37 8
Dead 1
Moribund Sacrifice 1
Animals Examined Microscopically 20 50 20 49
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (20) (44) (19) (43)
Intestine Large, Cecum (20) (48) (19) (47)
Intestine Small, Duodenum (20) (46) (19) (44)
Intestine Small, Ileum (20) (46) (19) (46)
Carcinoma 1 (2%)
Intestine Small, Jejunum (20) (46) (19) (46)
Liver (20) (50) (20) (49)
Hemangioma 1 (2%)
Hepatoblastoma 1 (2%) 1 (2%)
Hepatocellular Carcinoma 1 (5%) 12 (24%) 13 (27%)
Hepatocellular Carcinoma, Multiple 2 (4%) 3 (6%)
Hepatocellular Adenoma 1 (5%) 12 (24%) 3 (15%) 13 (27%)
Hepatocellular Adenoma, Multiple 5 (10%) 6 (12%)
Ito Cell Tumor Benign 1 (2%)
Pancreas (20) (50) (20) (49)
Carcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Acinus, Carcinoma 1 (2%)
Salivary Glands (20) (50) (20) (49)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (20) (50) (20) (49)
Carcinoma, Metastatic 1 (2%)
Carcinoma, Metastatic, Liver 1 (2%)
Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL CONTROL CONTROL 10 PPM 10 PPM 10 PPM
INTERIM TERMINAL NEURO INTERIM TERMINAL NEURO
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (20) (49) (20) (47)
Adenoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Islets, Pancreatic (20) (50) (20) (49)
Carcinoma, Metastatic, Liver 1 (2%)
Thyroid Gland (20) (49) (20) (48)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1)
Hepatocellular Carcinoma, Metastatic 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (20) (50) (20) (49)
Prostate (18) (45) (14) (49)
Seminal Vesicle (20) (50) (20) (49)
Testes (20) (50) (20) (49)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (20) (50) (20) (49)
Lymph Node (5) (50) (9) (48)
Lymph Node, Bronchial (3) (27) (4) (14)
Carcinoma, Metastatic, Liver 2 (7%)
Carcinoma, Metastatic, Lung 1 (7%)
Lymph Node, Mandibular (43) (41)
Lymph Node, Mediastinal (3) (22) (5) (9)
Carcinoma, Metastatic, Liver 1 (11%)
Lymph Node, Mesenteric (44) (1) (46)
Spleen (20) (50) (20) (49)
Thymus (18) (41) (19) (36)
Carcinoma, Metastatic, Liver 1 (2%) 1 (3%)
Carcinoma, Metastatic, Lung 1 (3%)
____________________________________________________________________________________________________________________________________
Page 12
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL CONTROL CONTROL 10 PPM 10 PPM 10 PPM
INTERIM TERMINAL NEURO INTERIM TERMINAL NEURO
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (20) (49) (20) (49)
Subcutaneous Tissue, Lipoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (19) (49) (20) (48)
Lung (20) (50) (20) (48)
Alveolar/Bronchiolar Adenoma 10 (20%) 1 (5%) 6 (13%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (4%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 8 (17%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Liver 6 (12%) 10 (21%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic 1 (2%)
Trachea (20) (49) (20) (48)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (2) (4)
Adenoma 2 (100%) 2 (50%)
Carcinoma 2 (50%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (20) (50) (20) (49)
Carcinoma, Metastatic 1 (2%)
Carcinoma, Metastatic, Liver 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Renal Tubule, Adenocarcinoma 1 (2%)
Urinary Bladder (20) (49) (20) (49)
Page 13
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL CONTROL CONTROL 10 PPM 10 PPM 10 PPM
INTERIM TERMINAL NEURO INTERIM TERMINAL NEURO
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Myxoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(20) *(50) *(20) *(49)
Lymphoma Malignant Lymphocytic 1 (2%) 1 (2%)
Lymphoma Malignant Mixed 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 14
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL CONTROL CONTROL 10 PPM 10 PPM 10 PPM
INTERIM TERMINAL NEURO INTERIM TERMINAL NEURO
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 2 37 3 41
Total Primary Neoplasms 2 56 4 64
Total Animals with Benign Neoplasms 1 29 3 25
Total Benign Neoplasms 1 36 4 31
Total Animals with Malignant Neoplasms 1 16 28
Total Malignant Neoplasms 1 20 33
Total Animals with Metastatic Neoplasms 7 11
Total Metastatic Neoplasm 20 17
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 15
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 33 PPM 33 PPM 33 PPM 100 PPM 100 PPM
INTERIM TERMINAL NEURO TERMINAL NEURO
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 20 50 16 70 16
Scheduled Sacrifice 19 8 4
Early Deaths
Dead 1 3 1 14 4
Moribund Sacrifice 5 2
Moribund 1 1 37 8
Accident 1
Survivors
Terminal Sacrifice 40 6 16
Moribund 1
Animals Examined Microscopically 20 50 2 70 12
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (19) (50) (2) (61) (11)
Intestine Small, Ileum (19) (50) (2) (61) (11)
Histiocytic Sarcoma 1 (2%)
Liver (20) (50) (2) (70) (12)
Hemangiosarcoma 1 (2%) 1 (1%)
Hepatocellular Carcinoma 8 (16%) 4 (6%)
Hepatocellular Carcinoma, Multiple 2 (4%)
Hepatocellular Adenoma 12 (24%) 6 (9%)
Hepatocellular Adenoma, Multiple 5 (10%) 1 (1%)
Histiocytic Sarcoma, Metastatic, Intestine
Small 1 (2%)
Mesentery (1) (2)
Hemangioma 1 (50%)
Pancreas (20) (50) (2) (70) (12)
Salivary Glands (20) (50) (2) (68) (12)
Stomach (20) (50) (2) (68) (12)
Stomach, Forestomach (20) (50) (2) (68) (12)
Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (20) (50) (2) (70) (12)
Carcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
Page 16
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 33 PPM 33 PPM 33 PPM 100 PPM 100 PPM
INTERIM TERMINAL NEURO TERMINAL NEURO
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (20) (50) (2) (68) (12)
Adrenal Gland, Medulla (20) (50) (2) (68) (12)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (20) (50) (2) (70) (12)
Adenoma 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (20) (50) (2) (69) (12)
Prostate (17) (45) (2) (66) (12)
Seminal Vesicle (20) (50) (2) (70) (12)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node (14) (50) (2) (58) (8)
Lymph Node, Bronchial (5) (21) (1) (18) (3)
Histiocytic Sarcoma, Metastatic, Intestine
Small 1 (5%)
Lymph Node, Mandibular (1) (43) (1) (27) (2)
Histiocytic Sarcoma, Metastatic, Intestine
Small 1 (2%)
Lymph Node, Mediastinal (9) (9) (1) (4) (1)
Lymph Node, Mesenteric (41) (1) (46) (7)
Histiocytic Sarcoma, Metastatic, Intestine
Small 1 (2%)
Spleen (20) (50) (2) (70) (11)
Hemangiosarcoma, Metastatic, Liver 1 (1%)
Histiocytic Sarcoma, Metastatic, Intestine
Small 1 (2%)
Thymus (18) (41) (1) (42) (6)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (20) (50) (2) (70) (12)
Hemangiosarcoma, Metastatic, Liver 1 (1%)
Tail, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 17
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 33 PPM 33 PPM 33 PPM 100 PPM 100 PPM
INTERIM TERMINAL NEURO TERMINAL NEURO
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (20) (50) (2) (70) (12)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (20) (50) (2) (70) (12)
Alveolar/Bronchiolar Adenoma 8 (16%) 4 (6%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (4%)
Alveolar/Bronchiolar Carcinoma 1 (5%) 5 (10%) 1 (1%)
Carcinoma, Metastatic 1 (1%)
Carcinoma, Metastatic, Liver 4 (8%) 1 (1%)
Histiocytic Sarcoma, Metastatic, Intestine
Small 1 (2%)
Nose (20) (50) (2) (69) (12)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1)
Adenoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (20) (50) (2) (70) (12)
Urinary Bladder (20) (47) (2) (68) (12)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(20) *(50) *(2) *(70) *(12)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%)
Lymphoma Malignant Mixed 3 (6%) 1 (1%)
Lymphoma Malignant Undifferentiated Cell 2 (4%) 1 (50%) 1 (1%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 18
NTP Experiment-Test: 05101-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL BROMIDE Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 18:38:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 33 PPM 33 PPM 33 PPM 100 PPM 100 PPM
INTERIM TERMINAL NEURO TERMINAL NEURO
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 1 38 1 16
Total Primary Neoplasms 1 56 1 20
Total Animals with Benign Neoplasms 28 10
Total Benign Neoplasms 31 12
Total Animals with Malignant Neoplasms 1 21 1 8
Total Malignant Neoplasms 1 25 1 8
Total Animals with Metastatic Neoplasms 5 3
Total Metastatic Neoplasm 11 4
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 19
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 115535-115535/115535
--multipart-boundary--